Literature DB >> 8328793

Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.

A Casadevall1, E D Spitzer, D Webb, M G Rinaldi.   

Abstract

Amphotericin B and fluconazole susceptibilities of 13 Cryptococcus neoformans isolates from five patients with recurrent cryptococcal meningitis were determined. For each patient, serial isolates showed no increase in antibiotic resistance relative to the initial isolate. For these patients, recurrent disease was not due to drug resistance but may reflect changes in immune function and/or poor compliance.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8328793      PMCID： PMC187974          DOI： 10.1128/AAC.37.6.1383

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Cryptococcal infections in patients with acquired immune deficiency syndrome.

Authors:  R H Eng; E Bishburg; S M Smith; R Kapila
Journal:  Am J Med       Date:  1986-07       Impact factor: 4.965

2.  Letter: Antagonism between miconazole and amphotericin B.

Authors:  L P Schacter; R J Owellen; H K Rathbun; B Buchanan
Journal:  Lancet       Date:  1976-08-07       Impact factor: 79.321

3.  Cryptococcosis in the acquired immunodeficiency syndrome.

Authors:  J A Kovacs; A A Kovacs; M Polis; W C Wright; V J Gill; C U Tuazon; E P Gelmann; H C Lane; R Longfield; G Overturf
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

4.  Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).

Authors:  K J Kwon-Chung; I Polacheck; J E Bennett
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

5.  Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans.

Authors:  I J Sud; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics.

Authors:  J Brajtburg; D Kobayashi; G Medoff; G S Kobayashi
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

7.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

8.  Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.

Authors:  J Mukherjee; L A Pirofski; M D Scharff; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.

Authors:  A Schaffner; P G Frick
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

Review 10.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191
View more
  37 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.

Authors:  N Poonwan; Y Mikami; S Poosuwan; J Boon-Long; N Mekha; M Kusum; K Yazawa; R Tanaka; K Nishimura; K Konyama
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

3.  Characterization of the virulence of Cryptococcus neoformans strains in an insect model.

Authors:  Tejas Bouklas; Elizabeth Diago-Navarro; Xiaobo Wang; Marc Fenster; Bettina C Fries
Journal:  Virulence       Date:  2015-09-12       Impact factor: 5.882

4.  Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.

Authors:  E J Anaissie; V L Paetznick; L G Ensign; A Espinel-Ingroff; J N Galgiani; C A Hitchcock; M LaRocco; T Patterson; M A Pfaller; J H Rex; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 5.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

6.  Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

Authors:  J Xu; C Onyewu; H J Yoell; R Y Ali; R J Vilgalys; T G Mitchell
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 7.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

8.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.

Authors:  S P Franzot; J S Hamdan
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.